LABU holdings - what the fund actually owns
Direxion Daily S&P Biotech Bull 3X Shares reports 145 stock positions to the SEC, 82% of its assets. The ten largest are 12.2% of the fund, as of Apr 30, 2026.
Each week Ploutos reads the latest N-PORT filing of the largest US equity ETFs. This page is one fund's filing: its reported positions with their weights, where that weight sits by sector, what entered and left since the previous filing, and which other funds hold the most of the same stocks.
Reported positions
145
cover 82% of the fund
Weight of the top 10 holdings
12.2%
of the fund in ten names
Largest position
APELLIS PHARMACEUTICALS INC
1.53% · Apellis Pharmaceuticals Inc
Filing date
Apr 30, 2026
holdings as reported to the SEC
Where the weight sits, by sector
Sectors come from each company's industry code in its SEC record, so they are coarse. 4.4% of the reported weight could not be placed and is shown as unknown.
Full holdings list, heaviest first
| # | Stock | Weight | Cumulative |
|---|---|---|---|
| 1 | APELLIS PHARMACEUTICALS INC | 1.53% | 1.5% |
| 2 | RVMDRevolution Medicines Inc | 1.35% | 2.9% |
| 3 | TVTXTravere Therapeutics Inc | 1.33% | 4.2% |
| 4 | ARWRARROWHEAD PHARMACEUTICALS INC | 1.18% | 5.4% |
| 5 | TWSTTwist Bioscience Corporation | 1.17% | 6.6% |
| 6 | SMMTSummit Therapeutics Inc. | 1.15% | 7.7% |
| 7 | ALKSAlkermes PLC | 1.14% | 8.9% |
| 8 | TGTXTG Therapeutics Inc | 1.13% | 10.0% |
| 9 | MDGLMadrigal Pharmaceuticals Inc | 1.12% | 11.1% |
| 10 | BEAMBeam Therapeutics Inc. | 1.09% | 12.2% |
| 11 | APGEApogee Therapeutics Inc. | 1.04% | 13.2% |
| 12 | SRRKScholar Rock Holding Corp. | 1.01% | 14.2% |
| 13 | EXELEXELIXIS INC | 1.00% | 15.2% |
| 14 | PRAXPRAXIS PRECISION MEDICINES INC | 1.00% | 16.2% |
| 15 | MIRMMirum Pharmaceuticals Inc. | 0.99% | 17.2% |
| 16 | CELCCelcuity Inc. | 0.98% | 18.2% |
| 17 | CRSPCRISPR Therapeutics AG | 0.98% | 19.2% |
| 18 | NTRANatera Inc. | 0.98% | 20.2% |
| 19 | UTHRUnited Therapeutics Corporation | 0.98% | 21.2% |
| 20 | KRYSKrystal Biotech Inc | 0.96% | 22.1% |
| 21 | PTGXProtagonist Therapeutics Inc | 0.96% | 23.1% |
| 22 | NBIXNEUROCRINE BIOSCIENCES INC | 0.95% | 24.0% |
| 23 | CGONCG Oncology Inc. | 0.94% | 25.0% |
| 24 | CYTKCytokinetics Inc | 0.94% | 25.9% |
| 25 | INCYIncyte Corporation. | 0.94% | 26.8% |
| 26 | IONSIonis Pharmaceuticals, Inc. | 0.94% | 27.8% |
| 27 | NUVALENT INC | 0.94% | 28.7% |
| 28 | BBIOBridgebio Pharma Inc | 0.93% | 29.7% |
| 29 | BIIBBiogen Inc | 0.93% | 30.6% |
| 30 | COGTCogent Biosciences Inc. | 0.93% | 31.5% |
| 31 | KYMRKymera Therapeutics Inc | 0.93% | 32.4% |
| 32 | PCVXVaxcyte Inc | 0.93% | 33.4% |
| 33 | PTCTPTC Therapeutics, Inc. | 0.93% | 34.3% |
| 34 | INSMInsmed Inc | 0.92% | 35.2% |
| 35 | ALNYALNYLAM PHARMACEUTICALS INC | 0.90% | 36.1% |
| 36 | HALOHalozyme Therapeutics Inc | 0.90% | 37.0% |
| 37 | ROIVRoivant Sciences Ltd | 0.90% | 37.9% |
| 38 | ARQTArcutis Biotherapeutics Inc. | 0.88% | 38.8% |
| 39 | SYRESpyre Therapeutics Inc | 0.88% | 39.7% |
| 40 | ABBVAbbVie Inc. | 0.87% | 40.6% |
| 41 | SOLENO THERAPEUTICS INC | 0.87% | 41.4% |
| 42 | AMGNAmgen Inc. | 0.86% | 42.3% |
| 43 | ACADACADIA PHARMACEUTICALS INC | 0.85% | 43.1% |
| 44 | RAREULTRAGENYX PHARMACEUTICAL INC | 0.85% | 44.0% |
| 45 | REGNREGENERON PHARMACEUTICALS INC | 0.85% | 44.8% |
| 46 | RYTMRhythm Pharmaceuticals Inc | 0.85% | 45.7% |
| 47 | BMRNBiomarin Pharmaceutical Inc. | 0.84% | 46.5% |
| 48 | GILDGilead Sciences Inc. | 0.84% | 47.4% |
| 49 | VKTXViking Therapeutics Inc. | 0.82% | 48.2% |
| 50 | VRTXVERTEX PHARMACEUTICALS INC | 0.81% | 49.0% |
| 51 | IBRXImmunityBio Inc | 0.80% | 49.8% |
| 52 | IMVTImmunovant Inc | 0.77% | 50.6% |
| 53 | MRNAModerna Inc | 0.77% | 51.3% |
| 54 | VERAVera Therapeutics Inc. | 0.75% | 52.1% |
| 55 | IMNMImmunome Inc | 0.74% | 52.8% |
| 56 | IRONDisc Medicine Inc | 0.74% | 53.6% |
| 57 | VCYTVeracyte Inc | 0.71% | 54.3% |
| 58 | CATALYST PHARMACEUTICALS INC. | 0.70% | 55.0% |
| 59 | SRPTSarepta Therapeutics Inc | 0.70% | 55.7% |
| 60 | BCRXBIOCRYST PHARMACEUTICALS INC | 0.67% | 56.3% |
| 61 | DYNDyne Therapeutics Inc. | 0.67% | 57.0% |
| 62 | KODKodiak Sciences Inc | 0.64% | 57.7% |
| 63 | RXRXRECURSION PHARMACEUTICALS INC | 0.64% | 58.3% |
| 64 | GRALGRAIL Inc | 0.63% | 58.9% |
| 65 | RCUSArcus Biosciences Inc. | 0.61% | 59.5% |
| 66 | AGIOAgios Pharmaceuticals Inc | 0.60% | 60.1% |
| 67 | DNLIDenali Therapeutics Inc | 0.59% | 60.7% |
| 68 | DNTHDianthus Therapeutics Inc | 0.57% | 61.3% |
| 69 | ORKAOruka Therapeutics Inc | 0.57% | 61.9% |
| 70 | ADMAADMA BIOLOGICS INC | 0.56% | 62.4% |
| 71 | ERASErasca Inc | 0.56% | 63.0% |
| 72 | NTLAIntellia Therapeutics Inc | 0.56% | 63.5% |
| 73 | SNDXSyndax Pharmaceuticals Inc. | 0.55% | 64.1% |
| 74 | ARDXArdelyx Inc | 0.54% | 64.6% |
| 75 | IDYAIDEAYA Biosciences Inc. | 0.52% | 65.2% |
| 76 | MLYSMineralys Therapeutics Inc. | 0.52% | 65.7% |
| 77 | NRIXNurix Therapeutics Inc. | 0.52% | 66.2% |
| 78 | TNGXTango Therapeutics Inc. | 0.47% | 66.7% |
| 79 | CLDXCelldex Therapeutics Inc. | 0.44% | 67.1% |
| 80 | CAPRCAPRICOR THERAPEUTICS INC | 0.43% | 67.5% |
| 81 | VCELVericel Corporation | 0.43% | 68.0% |
| 82 | GLUEMonte Rosa Therapeutics Inc | 0.42% | 68.4% |
| 83 | INBXInhibrx Biosciences Inc. | 0.42% | 68.8% |
| 84 | BHVNBiohaven Ltd | 0.41% | 69.2% |
| 85 | NVAXNovavax Inc | 0.41% | 69.6% |
| 86 | STOKStoke Therapeutics Inc | 0.41% | 70.0% |
| 87 | RLAYRelay Therapeutics Inc | 0.40% | 70.4% |
| 88 | TSHATaysha Gene Therapies Inc. | 0.40% | 70.8% |
| 89 | VRDNViridian Therapeutics Inc | 0.40% | 71.2% |
| 90 | OLMAOlema Pharmaceuticals Inc. | 0.39% | 71.6% |
| 91 | PVLAPalvella Therapeutics Inc. | 0.39% | 72.0% |
| 92 | ANABAnaptysBio Inc. | 0.37% | 72.4% |
| 93 | QUREUniqure N.V. | 0.37% | 72.8% |
| 94 | CRVSCorvus Pharmaceuticals Inc | 0.35% | 73.1% |
| 95 | CDNACaredx Inc | 0.34% | 73.4% |
| 96 | MNKDMANNKIND CORP | 0.34% | 73.8% |
| 97 | KALVISTA PHARMACEUTICALS INC | 0.32% | 74.1% |
| 98 | IOVAIovance Biotherapeutics Inc | 0.30% | 74.4% |
| 99 | GERNGERON CORP | 0.28% | 74.7% |
| 100 | PGENPrecigen Inc | 0.28% | 75.0% |
| 101 | VIRVIR Biotechnology Inc | 0.28% | 75.2% |
| 102 | SLSSELLAS LIFE SCIENCES GROUP INC | 0.26% | 75.5% |
| 103 | ABSIAbsci Corp. | 0.25% | 75.8% |
| 104 | ANNXAnnexon Inc | 0.25% | 76.0% |
| 105 | KURAKura Oncology Inc. | 0.25% | 76.3% |
| 106 | TYRATyra Biosciences Inc | 0.25% | 76.5% |
| 107 | AVBPArriVent BioPharma Inc. | 0.24% | 76.7% |
| 108 | ORICORIC Pharmaceuticals Inc. | 0.24% | 77.0% |
| 109 | SANASana Biotechnology Inc | 0.24% | 77.2% |
| 110 | JANXJanux Therapeutics Inc | 0.23% | 77.5% |
| 111 | RIGLRigel Pharmaceuticals Inc. | 0.23% | 77.7% |
| 112 | CTMXCytomx Therapeutics Inc | 0.21% | 77.9% |
| 113 | SVRASavara Inc | 0.21% | 78.1% |
| 114 | SPRYARS Pharmaceuticals Inc | 0.20% | 78.3% |
| 115 | CGEMCullinan Therapeutics Inc | 0.19% | 78.5% |
| 116 | IRWDIronwood Pharmaceuticals, Inc. | 0.19% | 78.7% |
| 117 | XNCRXencor Inc | 0.19% | 78.9% |
| 118 | ZBIOZENAS BIOPHARMA INC | 0.19% | 79.1% |
| 119 | SIONSionna Therapeutics Inc. | 0.18% | 79.2% |
| 120 | BCAXBicara Therapeutics Inc. | 0.17% | 79.4% |
| 121 | PURRHYPERLIQUID STRATEGIES INC | 0.17% | 79.6% |
| 122 | PRMEPrime Medicine Inc | 0.16% | 79.7% |
| 123 | EBSEmergent Biosolutions Inc | 0.15% | 79.9% |
| 124 | VORVOR BIOPHARMA INC | 0.15% | 80.0% |
| 125 | RGNXRegenxbio Inc. | 0.14% | 80.2% |
| 126 | VNDAVANDA PHARMACEUTICALS INC | 0.14% | 80.3% |
| 127 | FDMT4D MOLECULAR THERAPEUTICS INC | 0.13% | 80.5% |
| 128 | TRAXFIRST TRACKS BIOTHERAPEUTICS INC | 0.13% | 80.6% |
| 129 | ALLOALLOGENE THERAPEUTICS INC | 0.12% | 80.7% |
| 130 | ALTAltimmune Inc. | 0.12% | 80.8% |
| 131 | LXEOLexeo Therapeutics Inc | 0.12% | 80.9% |
| 132 | MYGNMyriad Genetics Inc. | 0.12% | 81.1% |
| 133 | PRTAProthena Corporation PLC | 0.12% | 81.2% |
| 134 | VSTMVerastem Inc | 0.12% | 81.3% |
| 135 | ABUSArbutus Biopharma Corp. | 0.11% | 81.4% |
| 136 | AVXLAnavex Life Sciences Corp. | 0.10% | 81.5% |
| 137 | OCGNOCUGEN INC | 0.10% | 81.6% |
| 138 | RCKTROCKET PHARMACEUTICALS INC | 0.10% | 81.7% |
| 139 | AKBAAkebia Therapeutics Inc. | 0.09% | 81.8% |
| 140 | IVVDInvivyd Inc | 0.09% | 81.9% |
| 141 | MDXGMiMedx Group Inc. | 0.09% | 82.0% |
| 142 | CATXPERSPECTIVE THERAPEUTICS INC | 0.08% | 82.1% |
| 143 | CMPXCompass Therapeutics Inc | 0.07% | 82.1% |
| 144 | REPLReplimune Group Inc | 0.06% | 82.2% |
| 145 | DMRADAMORA THERAPEUTICS INC | 0.03% | 82.2% |
Funds that hold the most of the same stocks
The share of LABU that is also in each fund, from the positions both report. Open a pair for the full list.
| Fund | Overlap | Shared |
|---|---|---|
| XBIState Street(R) SPDR(R) S&P(R) Biotech ETF | 76.5% | 137 |
| IBBiShares Biotechnology ETF | 39.0% | 118 |
| IWOiShares Russell 2000 Growth ETF | 13.3% | 91 |
| VHTVANGUARD HEALTH CARE INDEX FUND | 12.1% | 120 |
| VBKVANGUARD SMALL-CAP GROWTH INDEX FUND | 10.2% | 43 |
| IYHiShares U.S. Healthcare ETF | 9.4% | 23 |
| IWMiShares Russell 2000 ETF | 9.0% | 115 |
| ARKGARK Genomic Revolution ETF | 8.3% | 12 |
Questions people ask
What are the top holdings of LABU?
Its filing lists 145 stock positions. The largest are APELLIS PHARMACEUTICALS INC 1.5%, RVMD 1.4%, TVTX 1.3%, and the ten largest together are 12.2% of the fund. The full list with weights is on this page.
How often do these holdings change?
Funds report their positions to the SEC at each quarter end, and the SEC publishes the filing about 60 days later. Ploutos reads the latest one every week, so the page changes four times a year, and shows the date of the filing it reads.
Why does the coverage not reach 100%?
The list is the stock positions the fund reports. Cash, futures, bonds and other assets the filing carries are not listed, and what the stocks add up to is the coverage shown. A stock fund lands near 100; a fund that holds futures or a cash sleeve lands lower. Weights are of the whole fund.
Compare LABU with another fund·All fund pairs
Descriptive data from public SEC filings. Nothing on this page is a recommendation to buy, sell or hold any fund or stock, and holdings change between filings.